Market open · Delayed intraday data · 12:21 PM ET
Last update: Jun 29, 2026, 12:01 PM ET

Vertex Pharmaceuticals Incorporated (VRTX) — What Changed

$492.28+0.94 (+0.19%) today so far
Jun 29, 2026 12:21 PM ET·NASDAQ Global Select·Market Open·CEO: Reshma Kewalramani·6,100 employees

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The …

🔔Major Change Detected
Market Cap
$124.9B
Sector
Healthcare
Biotechnology
Next Earnings
Aug 2, 2026
(35 Days)
Relative Volume
0.40x
Below Avg
Risk Level
Low
Price Move
+0.19%
1-Day Change
Below 5D Avg: +-1.5%
Volume Confirmation
0.40x
vs 30D Average
Below Avg
Catalyst
Earnings Beat
Material / Earnings
Vertex Pharmaceuticals (VRTX) moved +5.4% after reporting EPS of $4.47, beating
Peer Context
Outperforming
Top 1 of 6 peers
Company-Specific Move
Signal Quality
Low
Confidence Score
54/100

BestStocks surfaces only meaningful changes—backed by price, volume, catalysts, and peer context—so you can focus on what matters.

1Event Reaction Chartⓘ
Price reaction around a key event
VRTXVertex Pharmaceuticals Incorporated$492.28+0.94 (+0.19%)
465.86472.47479.09485.71492.32Price (USD)Jun 22Jun 23Jun 24Jun 25Jun 26491.34
Price Move Up·Jun 26, 2026·+2.32% reaction

1. What Changed Since Last Close

F
New FilingMediumMedium
May 13

Vertex Pharmaceuticals (VRTX) filed an 8-K on May 13, 2026, with no stock price movement on that date (0% change).

›
F
New FilingMediumMedium
May 13

Vertex Pharmaceuticals (VRTX) filed an 8-K on May 13, 2026, with no stock price movement (0%) on the filing date.

›
E
Earnings BeatMediumMedium
May 4

Vertex Pharmaceuticals (VRTX) moved +5.4% after reporting EPS of $4.47, beating consensus estimates of $4.24 by 5.4%.

›
V
Price Move UpMediumMedium
Jun 26+2.32%2.9x vol

VRTX rose 2.68% to $493.03 intraday, building on a June 23 surge to $468.28 following Q1 2026 revenue of $2.99 billion.

›
E
Earnings BeatMediumMedium
Mar 31

Vertex Pharmaceuticals reported Q earnings of $4.47 per share, beating consensus estimates of $4.31 by 3.8%.

›
Showing 5 of 7 events

2. Change Timeline

DateChangePrice Reaction Volume Confidence ↓
May 13
FNew Filing
——Medium
May 13
FNew Filing
——Medium
May 4
EEarnings Beat
——Medium
Jun 26
VPrice Move Up
+2.32%2.9xMedium
Mar 31
EEarnings Beat
——Medium
Jun 29
VPrice Move Up
——Low
Jun 25
VPrice Move Up
+1.05%0.51xLow
Sort:  

3. Why It Moved

1
Primary Catalyst
Earnings Beat
Vertex Pharmaceuticals (VRTX) moved +5.4% after reporting EPS of $4.47, beating
2
Supporting Evidence
  • Vertex Pharmaceuticals (VRTX) moved +5.4% after reporting EPS of $4.47
  • VRTX rose 2.68% to $493.03 intraday, building on a June 23 surge to $4
  • Vertex Pharmaceuticals reported Q earnings of $4.47 per share, beating
  • Vertex Pharmaceuticals moved +1.05% from $475.20 to $480.18 on 2026-06
3
Nature of Move
Company-Specific Move
VRTX outperformed peers by more than expected sector variance — move appears company-specific.

4. Peer / Sector Confirmation

SymbolToday5DRel. Vol
VRTX+0.19%—0.40xLeader
LLY+7.13%——
UNH+2.97%——
JNJ+3.99%——
PFE+2.62%——
ABBV+4.20%——
Company-Specific Move. Top 1 of 6 peers. VRTX outperformed peers by more than expected sector variance — move appears company-specific.

5. SEC Filing Watch

May 13High
Material event — review for impact
May 5Medium
Quarterly financial results
May 4High
Material event — review for impact
Apr 29High
Material event — review for impact
Apr 2Low
Annual proxy — exec compensation & governance
Mar 31High
Material event — review for impact
View on SEC EDGAR →Source: filing_snapshots DB · past 120 days

6. Analyst Expectations

Consensus Target
$556.00
Median Target
$565.00
Upside to Target
+12.9%
vs $492.28
Analyst Activity — Last 90 Days
0
Upgrades
7
Maintains
0
Downgrades
Last Directional Actions
↑ Upgrade
Maxim Group · Hold → Buy
Mar 18, 2026
↓ Downgrade
Leerink Partners · Outperform → Market Perform
May 6, 2025

7. Bull vs Bear Thesis Shift

Bullish Factors
✓Earnings beat with positive market reaction
✓Positive 0.2% session move
✓Positive price momentum
✓Vertex Pharmaceuticals moved +1.05% from $475.20 to $480.18
Bearish Factors
✕New SEC filing — review for material disclosures
✕New SEC filing — review for material disclosures
Net Thesis Change vs Yesterday
BearishNeutralBullish
Bullish Shift+38 / 100

8. What To Watch Next

DateEventImpact
Aug 3Earnings ReleaseHigh
Aug 4est.10-Q FilingMedium
est. = estimated from prior filing cycle
🔔
9. Set Alerts & Get Notified
Get notified when VRTX reports earnings, files an 8-K, receives an analyst upgrade, or sees unusual volume.
✓ Earnings alerts
✓ Filing alerts
✓ Volume spikes
✓ Analyst actions

Educational research tool — not personalized investment advice. Data may be delayed.